ArticleReproductive sciences (Thousand Oaks, Calif.)2026
The Role of Four New Biochemical Markers in the Diagnosis and Prognosis of Ovarian Carcinoma.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to assess the diagnostic and prognostic value of four biochemical markers-PAX9, HK10, TBX2, and CYFRA21-1-in ovarian carcinoma (OC).
methodsWe conducted a prospective diagnostic study from December 2020 to December 2021, enrolling 88 patients with ovarian carcinoma, 90 with benign ovarian lesions, and 92 healthy controls. Blood levels of HK10 and CYFRA21-1 were measured, while tissue expressions of PAX9 and TBX2 were analyzed. We used logistic regression and ROC curve analysis to evaluate the diagnostic performance of these markers.
resultsThe OC group showed significantly higher positive expression rates of PAX9 and TBX2 compared to the benign group (65.91% vs. 4.44% and 26.14% vs. 3.33%, respectively). Additionally, HK10 and CYFRA21-1 levels were significantly elevated in the OC group compared to both the benign and healthy groups (P < 0.05). The expressions of all four markers were closely associated with clinical parameters such as tumor diameter, FIGO stage, degree of differentiation, and lymph node metastasis (P < 0.05). The sensitivity and specificity value of CA125, HK10, CYFRA21-1, PAX9, and TBX2 in the diagnosis of ovarian cancer were 85.09% and 80.09%, 65.87% and 61.67%, 81.25% and 79.59%, 75.32% and 74.49%, and 61.46% and 69.39%, respectively. The sensitivity and specificity of the combined biomarkers diagnosis are respectively 87.59% and 84.69%.
conclusionThe combined assessment of PAX9, HK10, TBX2, and CYFRA21-1 provides significant diagnostic and prognostic value in ovarian carcinoma, with HK10 showing particularly high sensitivity. These markers could play a crucial role in the early detection and management of ovarian carcinoma.
Indexed as
Identifiers
41331236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.